Baxdrostat

巴昔多司他

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameBaxdrostat
Drug Alias NameBaxfendyCIN-107RO-6836191RG-7641
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCytochrome P450 11B2 inhibitorsAldosterone synthase inhibitors
TargetsCytochrome P450 11B2
Therapy Area/IndicationsHyperaldosteronismHypertensionAtherosclerosis +[7] 
Global Approved IndicationsHypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2026/05/15
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca PharmaceuticalsAstrazeneca PlcAstrazeneca Ab +[4] 
Inactive CompaniesCinCor Pharma IncF. Hoffmann-La Roche Ltd
Active IndicationsHyperaldosteronismHypertensionHeart Failure +[5] 
Inactive IndicationsAtherosclerosisCardiovascular Diseases

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG